As drug makers increasingly grapple with other countries over the cost of medicines, the pharmaceutical industry’s trade group is asking the Trump administration to take “urgent action” against two dozen countries over their pricing policies and for engaging in “unfair” practices that threaten intellectual property rights.
In comments filed with the U.S. trade representative, the trade group also made a point of singling out Japan, South Korea, Malaysia, and Canada for various moves that will purportedly cost drug makers large amounts of sales and jeopardize their ability to develop innovative medicines.
“Biopharmaceutical innovators in the U.S. face a wide array of damaging pricing policies abroad that threaten billions of dollars in lost sales and put American jobs and exports at risk,” the Pharmaceutical Research and Manufacturers of America complained. The trade group also citied compulsory licensing as a particularly vexing issue.
About the Author Reprints
